|
Title
|
|
|
|
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m(2)) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m(2) on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m(2) paclitaxel with gemcitabine 1000 mg/m(2) in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Annals of oncology / European Society for Medical Oncology. - Amsterdam
| |
|
Publication
|
|
|
|
Amsterdam
:
2000
| |
|
ISSN
|
|
|
|
0923-7534
| |
|
DOI
|
|
|
|
10.1023/A:1008321000887
| |
|
Volume/pages
|
|
|
|
11
:1
(2000)
, p. 109-112
| |
|
ISI
|
|
|
|
000085191200024
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|